scPharmaceuticals (STU:2SX) FCF Margin % : -248.66% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is scPharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. scPharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was €-13.90 Mil. scPharmaceuticals's Revenue for the three months ended in Dec. 2023 was €5.59 Mil. Therefore, scPharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -248.66%.

As of today, scPharmaceuticals's current FCF Yield % is -36.03%.

The historical rank and industry rank for scPharmaceuticals's FCF Margin % or its related term are showing as below:

STU:2SX' s FCF Margin % Range Over the Past 10 Years
Min: -436.68 Med: -436.14 Max: -436.14
Current: -436.68

During the past 9 years, the highest FCF Margin % of scPharmaceuticals was -436.14%. The lowest was -436.68%. And the median was -436.14%.

STU:2SX's FCF Margin % is ranked worse than
64.82% of 1046 companies
in the Biotechnology industry
Industry Median: -145.305 vs STU:2SX: -436.68

scPharmaceuticals FCF Margin % Historical Data

The historical data trend for scPharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals FCF Margin % Chart

scPharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-436.13

scPharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-799.43	-863.23	-354.34	-248.66

Competitive Comparison of scPharmaceuticals's FCF Margin %

For the Biotechnology subindustry, scPharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

scPharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, scPharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where scPharmaceuticals's FCF Margin % falls into.

scPharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

scPharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-54.364	/	12.465
	=	-436.13 %

scPharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-13.9	/	5.59
	=	-248.66 %

scPharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

scPharmaceuticals (STU:2SX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (STU:2SX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SCPH:USA

Address

2400 District Avenue, Suite 310, Burlington, MA, USA, 01803

Website

https://www.scpharmaceuticals.com

scPharmaceuticals Inc is a pharmaceutical company. Its pipeline includes products in various stages of clinical and non-clinical development. It focuses on pharmaceutical products in the cardiovascular and infectious disease therapeutic areas. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

scPharmaceuticals (STU:2SX) Headlines

No Headlines